ALPMF - iTeos Therapeutics Begins U.S. IPO Rollout
Quick Take
iTeos Therapeutics (ITOS) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement.
The company is a clinical stage biopharma firm advancing a pipeline of immuno-oncology drug candidates for treating solid tumors and other cancers.
ITOS has produced promising early stage trial results for its lead candidate and has very large potential markets should it succeed.
I’ll provide an update when we learn more IPO details from management.
Company & Technology
Cambridge, Massachusetts-based iTeos was founded to develop treatments for a wide